|
Access to specialist care and treatment in patients with advanced non-small cell lung cancer. |
|
|
Consulting or Advisory Role - Biodesix; Boehringer Ingelheim; Otsuka |
Research Funding - Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst); Newlink Genetics (Inst); Pfizer (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Celgene |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly |
Research Funding - Millennium (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech; HTG, Inc.; Lilly; Merck; Pfizer; Roche; Ventana Medical Systems |
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst) |
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors, held by University of Colorado (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech (Inst) |
|
|
Consulting or Advisory Role - Genentech (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Novartis |
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer |